Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Pharmacokinetics of Survodutide in Healthy Male Volunteers
NCT05421338Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of survodutide in obesity, sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [14C]-radioactivity excreted in urine up to 7 weeks and Fraction of [14C]-radioactivity excreted in faeces up to 7 weeks. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05421338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421338.